Table 2 The correlation analysis between eight prognostic-related DEGs with clinical characteristics in the testing dataset
| Â | Total | Expression | p-value | |
|---|---|---|---|---|
High | Low | |||
(N = 170) | (N = 85) | (N = 85) | ||
Gender | ||||
Female | 79 (46.5%) | 39 (45.9%) | 40 (47.1%) | 1 |
Male | 91 (53.5%) | 46 (54.1%) | 45 (52.9%) | Â |
Age (years) | ||||
 >  = 60 | 119 (70.0%) | 52 (61.2%) | 67 (78.8%) | 0.019 |
 < 60 | 51 (30.0%) | 33 (38.8%) | 18 (21.2%) |  |
M | ||||
M0 | 137 (80.6%) | 63 (74.1%) | 74 (87.1%) | 0.046 |
M1 | 23 (13.5%) | 17 (20.0%) | 6 (7.1%) | Â |
MX | 10 (5.9%) | 5 (5.9%) | 5 (5.9%) | Â |
N | ||||
N0 | 94 (55.3%) | 34 (40.0%) | 60 (70.6%) |  < 0.001 |
N1 | 44 (25.9%) | 30 (35.3%) | 14 (16.5%) | Â |
N2 | 32 (18.8%) | 21 (24.7%) | 11 (12.9%) | Â |
T | ||||
T1 | 6 (3.5%) | 0 (0%) | 6 (7.1%) |  < 0.001 |
T2 | 38 (22.4%) | 11 (12.9%) | 27 (31.8%) | Â |
T3 | 110 (64.7%) | 60 (70.6%) | 50 (58.8%) | Â |
T4 | 16 (9.4%) | 14 (16.5%) | 2 (2.4%) | Â |
Stage | ||||
Stage I | 40 (23.5%) | 10 (11.8%) | 30 (35.3%) |  < 0.001 |
Stage II | 51 (30.0%) | 22 (25.9%) | 29 (34.1%) | Â |
Stage III | 55 (32.4%) | 35 (41.2%) | 20 (23.5%) | Â |
Stage IV | 24 (14.1%) | 18 (21.2%) | 6 (7.1%) | Â |